skip to content

Cambridge Immunology Network



Our  research interests lie at the interface of the tumour microenvironment, lymphatic  biology and immunology. We believe the non-cancer cells comprising the stroma,  especially those expressing a protein known as podoplanin, play an important  role in helping to a) protect a new tumour from our immune system and b) develop  and metastasise.

To understand how podoplanin expression within the tumour  microenvironment is able to help drive tumour progression and modulation of the  anti-tumour immune response, we take a multidisciplinary approach that integrates  3D co-culture systems, state-of-the-art microscopy techniques, genetically  modified tumour models and in vivo imaging.

      With the knowledge we gain, our  ultimate goal is to develop therapeutic platforms that exploit these features  to specifically target the tumour and supporting tissues.

Group members

Dr Luisa Pedro

Dr Matthew Lakins

Dr Angela Riedel

Jennifer Harris

Bastian Schmied


Key publications: 

Shields JD. Lymphatics: at the interface of immunity, tolerance and tumour metastasis. Microcirculation. 2011 May 16. doi: 10.1111/j.1549-8719.2011.00113.x. [Epub ahead of print]

Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science. 2010 May 7;328(5979):749-52.

Issa A, Le TX, Shoushtari AN, Shields JD, Swartz MA. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res. 2009 Jan 1;69(1):349-57.

Shields JD, Fleury ME, Yong C, Tomei AA, Randolph GJ, Swartz MA. Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell. 2007 Jun;11(6):526-38.

Dr Jacqueline   Shields
Not available for consultancy


Departments and institutes: 
Person keywords: 
stromal immunology